Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Status:
Completed

Trial end date:
2017-12-20

Target enrollment:

Participant gender:

The study is aimed to confirm that letrozole + PD 0332991 is safe and tolerable and to assess the effect of the combination on advanced breast cancer

Phase 2

Pfizer

Letrozole
Palbociclib